S-309309 is an orally active, selective MGAT2 inhibitor that can be utilized in metabolic-related research.

S-309309 administered at a dosage of 3 mg/kg orally twice daily over a period of 6-13 weeks, effectively reduced food intake and weight gain in high-fat diet (HFD)-induced obesity (DIO) mice [1]. It also led to a decrease in insulin resistance index, hepatic triglyceride content, and levels of plasma alanine aminotransferase and aspartate aminotransferase. Furthermore, there was a reduction in gene expression associated with fibrosis, an increase in energy expenditure, and an upregulation of genes related to the beta oxidation of long-chain fatty acids in the intestine.